Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
20 Sep 2017 EMA Recommends Granting a Marketing Authorisation for Trastuzumab Biosimilar Breast cancer - Gastrointestinal cancers - Anticancer agents & Biologic therapy
19 Sep 2017 EMA Recommends Granting a Marketing Authorisation for Niraparib Gynaecologic malignancies - Anticancer agents & Biologic therapy
18 Sep 2017 FDA Approves a Biosimilar to Bevacizumab Anticancer agents & Biologic therapy
15 Sep 2017 Questionnaire Designed for Adolescent and Young Adults with Cancer Elicits Their Views on Treatment Cancer in Special Situations
14 Sep 2017 Reports on Care Quality for Adolescent and Young Adult Cancer Patients Are Lacking in the Literature Cancer in Special Situations
12 Sep 2017 ESMO 2017 Press Release: Best Poster at ESMO 2017 Shows Positive Trials Twice as Likely to be Reported in Lay Press
12 Sep 2017 ESMO 2017 Press Release: Best of ESMO 2017 Congress
11 Sep 2017 ESMO 2017: Adjuvant Dabrafenib Plus Trametinib Significantly Lowers Risk of Death in Stage III BRAF V600–Mutated Melanoma Melanoma and other skin tumours - Anticancer agents & Biologic therapy
11 Sep 2017 ESMO 2017: Nivolumab Bests Ipilimumab as Adjuvant Therapy in Resected Melanoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: BRIM8 Data Shows Benefit with Adjuvant Vemurafenib in Resected BRAFV600 Positive Melanoma Melanoma and other skin tumours - Anticancer agents & Biologic therapy
11 Sep 2017 ESMO 2017: Single Agent Atezolizumab in Head and Neck Cancer Head and neck cancers - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: Nivolumab Demonstrates Antitumour Activity Post-progression in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Head and neck cancers - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: Durvalumab Shows Promising Clinical Benefit in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Head and neck cancers - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: Combined Therapy with Nivolumab and ISA 101 Vaccine Results in Promising Efficacy in HPV-positive Oropharyngeal Cancer Head and neck cancers - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: Rocapuldencel-T Shows Potential Benefit in Metastatic Renal Cell Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy